December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

25.79 -0.92 (-3.44%)
Delayed Quote Updated: 2:04 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Adaptive (ADPT) Q3 2026 Earnings Call Transcript ↗
Total company profitability arrived early as MRD guidance moved higher. 
Via The Motley Fool
Topics Earnings
News headline image
Adaptive Biotechnologies Q3 Earnings Call Highlights ↗
Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing... 
Via MarketBeat
Topics Earnings
News headline image
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance ↗
Via Chartmill
Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗
Via Chartmill
News headline image
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Q2 Earnings Call Highlights ↗
Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year... 
Via MarketBeat
Topics Earnings
News headline image
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run ↗
Harlan Robins liquidated 386,240 shares under a pre-scheduled Rule 10b5-1 trading plan, retaining over 1 million shares worth $21.6 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong year-over-year share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference ↗
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted... 
Via MarketBeat
News headline image
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive (ADPT) Q1 2026 Earnings Transcript ↗
Adaptive (ADPT) Q1 2026 Earnings Transcript 
Via The Motley Fool
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗
This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.